Digitize Validation for Remote Regulatory Reviews and Inspections


Originally published on IVT Network (www.ivtnetwork.com) | Journal of GxP Compliance | Volume 25, Issue 1 January 2021

In the on-going COVID-19 pandemic, the U.S. Food and Drug Administration has postponed domestic and foreign routine surveillance inspections on a case-by-case basis; it is prioritizing mission-critical inspections that it seeks to conduct with appropriate safety measures in place. In the broader context of extreme uncertainty and emergency use principles, the FDA is relying on firms to self-regulate – “we believe most FDA-regulated firms understand and appreciate their responsibility to ensure the safety of the products they manufacture or produce. We consider these firms to be our partners in public health” (1,2).

It is unlikely that we will return to the pre-pandemic “normal” course of regulatory inspection for some time; perhaps, the remote, virtual, “office-based” inspections may now be a part of the norm across the ICH region (3,4). This alternate means of inspections will, among other things, require firms to provide electronic copies of documents and additional information for off-site regulatory “review” with follow-up tele/video conferences and email. Inspecting and investigating deviations from Good Laboratory, Clinical, and Manufacturing Practices is a distinct complementary function to off-site regulatory review of documents supplied by a company. There is a need to appreciate the value of this distinction and to progress evidence-based policies and procedures incorporate technological solutions that provide remote “hands-on” and “eye-on” interactive inspectional capabilities.

Paperless validation systems are already in place at many facilities. They can be utilized for interactive inspections and provide opportunities for regulators and companies to improve efficiencies and provide assurance to patients. This paper outlines key advantages and points to consider for leveraging a paperless validation platform to enhance the efficiency of remote pre-approval and pre-license remote inspections.

The opinions, information and conclusions contained within this blog should not be construed as conclusive fact, ValGenesis offering advice, nor as an indication of future results.